enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series

enVVeno Medical’s new “WTF Rob Berman” video series offers investors candid updates on its venous valve technology, trials and commercialization plans.

Rhea-AI Summary

enVVeno Medical (NVNO) launched a new CEO-led video series, “WTF Rob Berman,” on September 16, 2026, aimed at giving investors direct, plain‑spoken information about the company.

Hosted by CEO Rob Berman, the series is intended to move beyond scripted corporate messaging and offer candid, fact‑driven discussion of enVVeno’s technology, clinical programs, regulatory and development progress, upcoming milestones, and corporate decision‑making. Episodes will address topics such as the enVVe® System, the path toward the SAVVE pivotal trial, enVVeno’s venous valve replacement approach, and its strategy toward potential commercialization. The company notes severe deep venous insufficiency (DVI) affects an estimated 3 million people in the U.S. and that the enVVe System is being developed as a potential first‑in‑class bioprosthetic venous valve replacement.

Key Terms

bioprosthetic, deep venous insufficiency, pivotal trial, chronic venous insufficiency

4 terms

bioprosthetic medical

"late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic"

A bioprosthetic is a medical implant made from biological tissues—often animal or human-derived—used to replace or support body parts like heart valves or joints. Think of it as a natural-material replacement part that mimics living tissue; it matters to investors because its performance, durability, manufacturing complexity, and regulatory approval drive clinical adoption, repeat procedures, reimbursement and long-term revenue potential for companies that develop or sell these devices.

deep venous insufficiency medical

"its potential to address severe DVIClinical development and the road toward the SAVVE pivotal trial"

Deep venous insufficiency is a condition where the one-way valves in the deep veins of the legs fail, letting blood pool or flow backward instead of returning efficiently to the heart — imagine valves in a pipe that no longer close properly. For investors, it matters because it drives demand for treatments, diagnostic tests and medical devices, influences healthcare spending and reimbursement trends, and can affect the commercial prospects and regulatory risk for companies developing related therapies.

pivotal trial regulatory

"Clinical development and the road toward the SAVVE pivotal trial"

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

chronic venous insufficiency medical

"focuses on Chronic Venous Insufficiency (CVI), what it is"

A long-term condition in which the one-way valves in leg veins do not work properly, causing blood to pool, swelling, pain, skin changes or ulcers; think of it as a plumbing problem where backflow wears out pipes and fixtures. Investors care because it is a common, chronic market with ongoing demand for treatments, devices and wound-care products, and outcomes depend on clinical data, regulatory approvals and reimbursement decisions that affect revenue streams.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New CEO-led video series provides investors with straight talk, just the facts, with no B.S. or corporate spin

Real answers to what investors need to know about enVVeno and why they need to know it

Watch the inaugural episode here

IRVINE, CA / ACCESS Newswire / September 16, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced the launch of "WTF Rob Berman" a new video series that provides the information that investors need to know, in straight talk, with no corporate spin.

Hosted by enVVeno Medical CEO Rob Berman, the WTF series is designed to go beyond the usual scripted corporate answers used by public company CEOs. Instead, investors will get a candid, accessible and fact-driven look inside the Company, including its technology, clinical programs, regulatory and development progress, upcoming milestones and the decisions shaping its path forward.

The premise is simple: cut through the noise, get to the facts and tell investors what they need to know and why it matters.

"In today's environment, investors are inundated with so much information from so many different sources, it's hard for them to tell what is fact and what is fiction. We created the WTF "with the facts" series to cut through the noise and make it easier for investors to get the information they really need, including easy to understand explanations of why they need it," said Rob Berman, CEO of enVVeno Medical. "We also wanted to have some fun along the way. There is no reason why a video series cannot be both informative and fun at the same time. Not everybody enjoys reading SEC filings, and we wanted to come up with alternative ways to get our messaging out to investors."

The inaugural episode is now available, with additional episodes planned as enVVeno advances its clinical and corporate milestones.

The series will cover topics including:

• The enVVe^® System and its potential to address severe DVI
• Clinical development and the road toward the SAVVE pivotal trial
• The significant unmet need facing patients with severe DVI
• The Company's technology and approach to venous valve replacement
• Key developments investors should be watching
• enVVeno's strategy and priorities as it advances toward potential commercialization

Approximately 3 million people in the U.S. are estimated to live with severe DVI, a debilitating condition for which there are currently limited treatment options. enVVeno is developing the enVVe System as a potential first-in-class bioprosthetic venous valve replacement designed to restore the function of damaged venous valves.

Watch the second episode of "WTF Rob Berman" here, which focuses on Chronic Venous Insufficiency (CVI), what it is and why it represents a compelling investment opportunity.

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

INVESTOR CONTACT:

JTC Team, LLC
Jenene Thomas
NVNO@jtcir.com
(908) 824-0775

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the focus of the new “WTF Rob Berman” video series?

The “WTF Rob Berman” series focuses on giving investors straightforward, fact‑based insight into enVVeno Medical, including its technology, clinical programs, regulatory and development progress, upcoming milestones, and the decisions shaping the company’s path forward.

Which specific topics will upcoming episodes of the series cover?

Planned topics include the enVVe® System and its potential to address severe deep venous insufficiency (DVI), clinical development and the road toward the SAVVE pivotal trial, the unmet need in severe DVI, enVVeno’s venous valve replacement technology and approach, key developments investors should monitor, and the company’s strategy and priorities as it advances toward potential commercialization.

What condition is enVVeno targeting with the enVVe System and how large is the affected population?

The enVVe System is being developed for patients with severe deep venous insufficiency (DVI), a debilitating condition with limited treatment options. Approximately 3 million people in the U.S. are estimated to live with severe DVI.

How does enVVeno describe the enVVe System?

enVVeno is developing the enVVe System as a potential first‑in‑class bioprosthetic venous valve replacement designed to restore the function of damaged venous valves in patients with deep venous disease.

What additional content is highlighted beyond the inaugural episode?

The company highlights a second episode of “WTF Rob Berman” that focuses on Chronic Venous Insufficiency (CVI), explaining what it is and why the company views it as a compelling investment opportunity.